Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial

BACKGROUND: The ATLAS trial compared axitinib versus placebo in patients with locoregional renal cell carcinoma (RCC) at risk of recurrence after nephrectomy. PATIENTS AND METHODS: In a phase III, randomized, double-blind trial, patients had >50% clear-cell RCC, had undergone nephrectomy, and had...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Ann Oncol
Egile Nagusiak: Gross-Goupil, M, Kwon, T G, Eto, M, Ye, D, Miyake, H, Seo, S I, Byun, S -S, Lee, J L, Master, V, Jin, J, DeBenedetto, R, Linke, R, Casey, M, Rosbrook, B, Lechuga, M, Valota, O, Grande, E, Quinn, D I
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2018
Gaiak:
Original Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6311952/
https://ncbi.nlm.nih.gov/pubmed/30346481
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdy454
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak